Table 4.
Examples of clinical trials testing senolytic drugs in the context of cancer.
| Senolytic drug | CT phase | Cancer | Senescence induction | CT number |
|---|---|---|---|---|
| Navitoclax | Phase 1 | Small cell lung cancer | Etoposide, cisplatin | NCT00878449 |
| Navitoclax | Phase 1 | Solid tumours | Erlotinib, irinotecan | NCT01009073 |
| Navitoclax | Phase 1 | Solid tumours | Gemcitabine | NCT00887757 |
| Navitoclax | Phase 1 | Solid tumours | Paclitaxel | NCT00891605 |
| Navitoclax | Phase 1/2 | Solid tumours | Trametinib | NCT02079740 |
| Navitoclax | Phase 1 | Solid tumours | Docetaxel | NCT00888108 |
| Navitoclax | Phase 1/2 | Solid tumours | Dabrafenib, trametinib | NCT01989585 |
| Navitoclax | Phase 1 | Advanced or metastatic non‐small cell lung cancer | Osimertinib | NCT02520778 |
| Navitoclax | Phase 1 | High‐grade serous carcinoma, triple‐negative breast cancer | Olaparib | NCT05358639 |
| Navitoclax | Phase 1 | Myeloid Neoplasms | Decitabine | NCT05455294 |
| Navitoclax | Phase 1 | Refractory acute myeloid leukaemia | Decitabine | NCT05222984 |
| Dasatinib and quercetin / Fisetin | Phase 2 | Childhood cancer survivors | N/A | NCT04733534 |